Serum chemokine levels and liver fibrosis accompanying transient abnormal myelopoiesis in Down syndrome

• Project/Area Number: 22791032
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Kyushu University
• Principal Investigator: TADAMUNE Kinjo 九州大学, 大学病院, 助教 (70419539)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: ダウン症 / TAM / 肝線維化 / ケモカイン / CCL2 / TGF-β1 / ダウン / マイクロアレイ

Research Abstract

Transient abnormal myelopoiesis (TAM) occurs in infants with Down syndrome. While most TAM patients ha ve a favorable clinical course, early death occurs in some patients. The main causes of death are organ failure, particularly hepatic failure due to hepatic fibrosis. The involvement of some growth factors and cytokines in the development of hepatic fibrosis was suspected. We investigated the association of circulating chemokines and TGF-β1 with TAM. Serum CCL2 levels were higher in infants with liver failure than in those without. CCL2 might affect the development of liver fibrosis.